Nephrology and Renal Diseases

Therapeutic Expertise Nephrology and Renal Diseases

In-depth clinical trial expertise in renal disease

We have significant experience in the design, planning and execution of Phase I-IV full service global trials in renal diseases. Our nephrology team has in-depth insight into the scientific methodology, competitive research landscape and key regulatory drivers to move product development forward quickly.

Our nephrology/renal disease global investigator network consists of nephrologists, critical care specialists, endocrinologists, internists and key opinion leaders, as well as a broad number of academic sites and dialysis centers that enable us to provide robust feasibility and consulting services across a wide spectrum of renal disease indications.

We recognize that patients with renal disease often face the burden of living with other comorbidities that take a toll on their quality of life and life expectancy. We have developed a comprehensive team of medical experts across various therapeutic areas, including metabolic, cardiovascular and autoimmune, to ensure holistic patient care. This integrated team of medical experts provide our clients with sound strategic guidance to drive efficient and effective clinical trials that address the challenges associated with renal diseases.

Connect with us to discuss our renal disease capabilities

Explore the latest industry trends and clinical advancements from leading nephrology experts

Watch our Nephrology Talks series

0 +

Studies

0 +

Patients

0 +

Sites

Renal and nephrology clinical study experience

Our comprehensive renal and nephrology clinical study experience spans a broad range of indications including:

Chronic renal disease and end stage renal disease
Diabetic nephropathy
Hyperphosphatemia
Vasculitis (i.e., SLE)
Acute kidney injury
Anemia
Glomerulonephritis (i.e., IgA nephropathy and focal glomerulosclerosis)
Hyperoxaluria
Kidney transplantation
Polycystic kidney disease
Alport syndrome

Additionally, our team has experience working with pediatric and rare renal conditions, having conducted 27 rare renal disease studies over the past five years.

Advancing treatments for CKD and Rare Renal Disorders: Our experts weigh in
Experts address a high unmet need for advancing treatments for rare renal diseases

Advancing renal disease clinical research in peri-and post- approval settings

Our Evidera peri- and post-approval business specializing in evidence, value and access, brings extensive experience across the spectrum of nephrology indications, including chronic kidney disease, diabetic kidney disease, end stage renal disease, renal transplants and renal cell carcinoma. We have completed approximately 150 engagements in nephrology over the past five years across our service offerings and in markets around the globe. This work also includes 22 real-world evidence studies. Our work has addressed a broad range of issues such as treatment sequencing, humanistic and economic burden of disease and epidemiological and market access research. We have also published 70 papers in peer-reviewed and non-peer reviewed journals, such as Immunotherapy, Transplantation, Clinical Therapeutics, the International Journal of Nephrology and the Journal of Clinical Pharmacology.

Partner with a global multi-specialty team in renal disease

**Andy Bevan**
Executive Director,
Peri- and Post-approval Studies

**Carmichael Angeles, MD**
Senior Medical Director
Pharmacovigilance
Board Certified Nephrologist

**Davide Garrisi**
Nephrology, GU, Renal and Metabolic Therapeutic Area Lead

**Sarah Dixon Stump**
Senior Director,
Project Management

Meet our nephrology experts

Modeling Diversity in Diabetic Kidney Disease Clinical Trials

Compare the demographics of individuals diagnosed with Diabetic Kidney Disease (DKD) with those represented in US-only DKD clinical trials to support a more inclusive and representative participant pool.